Our key milestones
*at Teoxane Laboratories
- All products of the TEOSYAL® Classic, TEOSYAL® PURESENSE and TEOSYAL RHA® lines, including TEOSYAL® ULTRA DEEP, TEOSYAL KISS®, TEOSYAL PURESENSE ® REDENSITY 1 & 2, and TEOSYAL RHA® 1 to 4, are trademarks of the firm TEOXANE SA. They are class III medical devices and are regulated health products bearing the CE marking (CE0086) under this regulation. They are available in around 80 countries, excluding the US. For professional use only. Please refer to instructions for use. TEOSYAL® PURESENSE and TEOSYAL® RHA products are gels that contain hyaluronic acid, and 0.3% by weight of lidocaine hydrochloride (local anaesthetic can induce a positive reaction to anti-doping tests).
- Products of the TEOXANE Cosmeceutical range are cosmetic products according to European Regulation 1223/2009, except Radiant Night Peel which is a class I medical device, according to Directive 93/42/EEC. Cosmeceuticals products are not designed to be injected.
- TEOSYAL® PEN is a non-sterile class IIa medical device (CE0434) intended to assist medical practitioner for dermal filler injections. Manufactured by JuvaPlus in Switzerland. For more information, please consult the user guide of TEOSYAL® PEN or the recommendations available on www.teosyalpen.com. Please refer to instructions for use. It is the practitioner’s full responsibility to read and inform the patient about adverse reaction.
- RHA® is a trademark of TEOXANE SA. RHA® 2, RHA® 3, RHA® 4 are products of TEOXANE SA. They are class III medical devices and have received FDA approval but are not yet commercialized in the United States. The United States Federal law restricts these devices to sale by or on the order of a physician or license practitioner. RHA® 2, RHA® 3 and RHA® 4 are indicated for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLF), in adults aged 22 years or older. RHA® 2, RHA® 3, and RHA® 4 are sterile gels containing crosslinked hyaluronic acid in physiological buffer and 0.3% lidocaine hydrochloride to reduce pain on injection. RHA® 2, RHA® 3 and RHA® 4 are contraindicated in patients with previous hypersensitivity to local anaesthetics of the amide type, such as lidocaine. Please refer to the Instructions for Use (https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170002C.pdf). It is the practitioner’s full responsibility to read and inform the patient about contraindications, warnings, precautions, risks and benefits.